Key facts
- Diakonos Oncology presented updated DOC1021 data for glioblastoma.
- The data showed 90% 12-month overall survival in a predominantly MGMT-unmethylated population.
- Immune analyses suggest immune memory.
- Diakonos Oncology launched a clinical study for DOC1021 in refractory melanoma.
Diakonos Oncology has released updated clinical trial data for its drug candidate, DOC1021, in the treatment of newly diagnosed glioblastoma (GBM). The presented data indicate a 90% overall survival rate at 12 months within a patient group that was predominantly MGMT-unmethylated. Accompanying immune analyses suggest that DOC1021 may induce immune memory. In addition to these GBM findings, Diakonos Oncology has initiated a new clinical study for DOC1021, focusing on patients with refractory melanoma.